The Global Medical Devices Reimbursement Market was valued at USD 617.6 billion in 2025 and is estimated to grow at a CAGR of 6.5% to reach USD 1.2 trillion by 2035.
The market expansion is driven by rising healthcare expenditures, increasing prevalence of chronic illnesses, and supportive government initiatives promoting access to medical devices. The adoption of value-based healthcare models has also reshaped reimbursement frameworks, emphasizing clinical effectiveness and cost-efficiency. Medical device reimbursement involves compensating healthcare providers, including hospitals, clinics, and surgical centers, for the acquisition, maintenance, and use of devices in diagnosis, monitoring, and treatment. Reimbursement structures are evolving with new payment models, coverage criteria, and market access pathways, creating opportunities for innovative devices that improve patient outcomes and reduce overall healthcare costs. These transformative trends are strengthening the integration of medical devices into modern healthcare systems while ensuring financial sustainability.
The private payer segment held a 63.3% share in 2025. Private insurers, employer-sponsored plans, and supplemental policies generally offer faster coverage decisions and more favorable payment rates than public payers. Private coverage is also more likely to include advanced or premium devices. Growth in this segment is supported by rising middle- and high-income populations, particularly in the Asia-Pacific region, where private insurance adoption is increasing.
The hospitals segment accounted for 50.8% share in 2025. Reimbursement in hospitals includes inpatient, outpatient, ambulatory surgical centers, and emergency departments. Growth is fueled by higher surgical volumes, adoption of advanced technologies, and broader reimbursement for complex procedures. Many devices are reimbursed as part of bundled payments, such as procedure fees or diagnosis-related groups, rather than on an individual device basis.
North America Medical Devices Reimbursement Market held 47.2% share in 2025. The U.S. market benefits from a large healthcare economy, established reimbursement infrastructure, regulatory clarity, and advanced adoption of medical technologies. Public and private spending ensures coverage for premium medical devices and supports market stability.
Key players in the Global Medical Devices Reimbursement Market include Allianz, Anthem Insurance Companies, Inc., Aviva, BNP Paribas, Cigna, CVS Health, Experian Health, Humana Inc., Nippon Life Insurance Company, United Health Group, and WellCare Health Plans, Inc. Companies in the Medical Devices Reimbursement Market strengthen their presence through multiple strategies. They focus on expanding private payer partnerships, offering tailored coverage plans for innovative devices, and negotiating favorable payment terms. Investments in digital claims management, real-time reimbursement analytics, and regulatory compliance tools improve operational efficiency. Firms also develop education programs for healthcare providers to increase adoption of reimbursed devices and demonstrate clinical and economic value. Strategic collaborations with hospitals, insurers, and technology providers enhance market penetration, while ongoing monitoring of evolving policies ensures adaptability to new payment models.
This product will be delivered within 2-4 business days.
The market expansion is driven by rising healthcare expenditures, increasing prevalence of chronic illnesses, and supportive government initiatives promoting access to medical devices. The adoption of value-based healthcare models has also reshaped reimbursement frameworks, emphasizing clinical effectiveness and cost-efficiency. Medical device reimbursement involves compensating healthcare providers, including hospitals, clinics, and surgical centers, for the acquisition, maintenance, and use of devices in diagnosis, monitoring, and treatment. Reimbursement structures are evolving with new payment models, coverage criteria, and market access pathways, creating opportunities for innovative devices that improve patient outcomes and reduce overall healthcare costs. These transformative trends are strengthening the integration of medical devices into modern healthcare systems while ensuring financial sustainability.
The private payer segment held a 63.3% share in 2025. Private insurers, employer-sponsored plans, and supplemental policies generally offer faster coverage decisions and more favorable payment rates than public payers. Private coverage is also more likely to include advanced or premium devices. Growth in this segment is supported by rising middle- and high-income populations, particularly in the Asia-Pacific region, where private insurance adoption is increasing.
The hospitals segment accounted for 50.8% share in 2025. Reimbursement in hospitals includes inpatient, outpatient, ambulatory surgical centers, and emergency departments. Growth is fueled by higher surgical volumes, adoption of advanced technologies, and broader reimbursement for complex procedures. Many devices are reimbursed as part of bundled payments, such as procedure fees or diagnosis-related groups, rather than on an individual device basis.
North America Medical Devices Reimbursement Market held 47.2% share in 2025. The U.S. market benefits from a large healthcare economy, established reimbursement infrastructure, regulatory clarity, and advanced adoption of medical technologies. Public and private spending ensures coverage for premium medical devices and supports market stability.
Key players in the Global Medical Devices Reimbursement Market include Allianz, Anthem Insurance Companies, Inc., Aviva, BNP Paribas, Cigna, CVS Health, Experian Health, Humana Inc., Nippon Life Insurance Company, United Health Group, and WellCare Health Plans, Inc. Companies in the Medical Devices Reimbursement Market strengthen their presence through multiple strategies. They focus on expanding private payer partnerships, offering tailored coverage plans for innovative devices, and negotiating favorable payment terms. Investments in digital claims management, real-time reimbursement analytics, and regulatory compliance tools improve operational efficiency. Firms also develop education programs for healthcare providers to increase adoption of reimbursed devices and demonstrate clinical and economic value. Strategic collaborations with hospitals, insurers, and technology providers enhance market penetration, while ongoing monitoring of evolving policies ensures adaptability to new payment models.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Payer, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Healthcare Setting, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The companies profiled in this Medical Devices Reimbursement market report include:- Allianz
- Anthem Insurance Companies, Inc.
- Aviva
- BNP Paribas
- Cigna
- CVS Health
- Experian Health
- Humana Inc.
- Nippon Life Insurance Company
- United Health Group
- WellCare Health Plans, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | February 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 617.6 Billion |
| Forecasted Market Value ( USD | $ 1200 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
